Inhalation and Oral drug development experts
Transcription
Inhalation and Oral drug development experts
Fact Sheet Inhalation and Oral drug development experts Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative Oral and Inhalation pharmaceutical products. The Group’s ideas, expertise and technologies are used by major companies around the world, including GSK, Sanofi, Mundipharma and Kyorin. Revenues are generated from 16 products, eight of which have been approved and launched in key markets in the last three years. With a strong balance sheet, Skyepharma is investing in new concepts, products and technologies to drive the next phase of growth. Oral Modified Release Inhalation Drug Development Skyepharma’s oral drug delivery expertise extends from formulation to process development and scale-up, and from technology transfer and regulatory affairs to commercial manufacture. These capabilities are combined with a growing range of proprietary technologies that control when and how orally administered drugs are delivered into the body. Skyepharma is a leading independent partner for the development of inhaled products. From R&D headquarters in Switzerland, it has proven capabilities to develop an inhaled therapy from early-stage concept through to regulatory approval and product supply. The Group’s expertise and technologies cover both Dry Powder (DPI) and pressurised Metered Dose (pMDI) Inhalers. Skyepharma technologies are used in 10 oral products marketed by leading companies in more than 80 countries. They have helped patients worldwide, generated more than $3 billion of sales for our partners over the past five years and are incorporated in some of the world’s best known products. Skyepharma’s researchers are working on innovative new approaches to continue to improve the way drugs are delivered. Our Partners Skyepharma and its partners recently completed development of a unique inhaled combination product, flutiform®, which has been approved in 35 countries. Further indications and a breathactuated version are in development. Skyepharma’s technology has been licensed to GSK for use in Breo® / Relvar®, Anoro® and Incruse®. Skyepharma recently acquired a novel inhaled therapy platform and is developing SKP2075 as a potential anti-inflammatory treatment for COPD. Key Contacts Peter Grant, CEO Andrew Derodra, CFO Tel: +44 (0) 20 7881 0524 [email protected] Skyepharma PLC 46-48 Grosvenor Gardens London SW1W 0EB www.skyepharma.com +44 (0) 20 7881 0524 March 2015 Corporate Summary Flexibility and resources to invest in new products, technologies and corporate opportunities Updated March 3 2015 LSE: SKP Shares Outstanding: 104.8m Market Cap: £321.8m Year High: 373.00p Year Low: 97.65p Board Peter Grant, CEO Andrew Derodra, CFO Non-Executive Directors: Frank Condella, Chairman Jean-Charles Tschudin, Dr Thomas Werner John Biles Major Shareholders Financial summary HBM Healthcare Investments BlackRock Aviva Investors Legal & General Standard Life Investments Analyst Coverage N+1 Singer (Company broker) Oriel Securities Rx Securities Edison Recent announcements Media / IR contacts 13 Feb 2015 Notice of early repayment of remainder of CRC Finance 12 Jan 2015 Pre-close update 01 Dec 2014 Kyorin launches flutiform 120-puff version +44 (0) 7860 361746 01 Dec 2014 flutiform [email protected] 09 Oct 2014 Interim Management Statement Skyepharma Jonathan Birt ® ® launch in Spain; Abriff ® launch in Italy 22 Sept 2014 Notice of early repayment of Euro CRC Facility FTI Consulting Julia Phillips / Rob Winder / Natalie Garland-Collins 08 Sept 2014 flutiform 21 Aug 2014 ® phase III results in paediatric asthma +44 (0) 20 3727 1000 Half-yearly report Skyepharma PLC 46-48 Grosvenor Gardens London SW1W 0EB www.skyepharma.com +44 (0) 20 7881 0524 March 2015